Skip to main content
. 2022 Jul 5;32(7):303–313. doi: 10.2188/jea.JE20200399

Table 6. Crude mortality rates and hazard ratios for ASCVD mortality according to non-fasting triglyceride category stratified by age <65 and ≥65 years.

  Baseline non-fasting triglyceride level
≤59 mg/dL 60–89 mg/dL 90–119 mg/dL 120–149 mg/dL 150–179 mg/dL 180–209 mg/dL ≥210 mg/dL
ASCVD death
Age <65 years
Men
Number of participants 176 432 468 311 249 172 430
Person-years 3,238 8,080 8,824 5,864 4,671 3,239 8,085
Number of deaths 4 6 10 5 2 1 9
Crude mortality rate 1.2 0.7 1.1 0.9 0.4 0.3 1.1
Hazard ratio (95% CI)              
 Model 1 2.64 (0.48–14.41) 1.57 (0.31–7.79) 2.29 (0.50–10.48) 1.97 (0.38–10.17) Ref. 0.77 (0.07–8.53) 2.77 (0.59–12.82)
 Model 2 2.33 (0.38–14.15) 1.66 (0.32–8.58) 2.09 (0.44–9.84) 1.72 (0.33–9.02) Ref. 0.68 (0.06–7.60) 2.22 (0.46–10.61)
 Model 3 2.54 (0.38–16.93) 1.76 (0.32–9.47) 2.18 (0.45–10.47) 1.76 (0.33–9.26) Ref. 0.68 (0.06–7.66) 2.17 (0.45–10.45)
 
Women
Number of participants 571 888 634 434 241 145 269
Person-years 11,176 17,310 12,287 8,386 4,657 2,770 5,180
Number of deaths 0 4 4 1 2 1 2
Crude mortality rate 0 0.2 0.3 0.1 0.4 0.4 0.4
Hazard ratio (95% CI)              
 Model 1 0.92 1.01 0.28 Ref. 0.83 0.85
(0.16–5.11) (0.18–5.55) (0.02–3.11) (0.07–9.23) (0.12–6.06)
 Model 2 0.89 0.93 0.31 Ref. 0.97 0.93
(0.14–5.45) (0.16–5.32) (0.02–3.55) (0.08–10.87) (0.12–6.84)
 Model 3 2.06 1.60 0.44 Ref. 0.93 0.62
(0.28–14.80) (0.26–9.71) (0.03–5.15) (0.08–10.50) (0.08–4.61)
 
Total
Number of participants 747 1,320 1,102 745 490 317 699
Person-years 14,414 25,390 21,111 14,250 9,328 6,009 13,265
Number of deaths 4 10 14 6 4 2 11
Crude mortality rate 0.3 0.4 0.7 0.4 0.4 0.3 0.8
Hazard ratio (95% CI)              
 Model 1 1.19 (0.29–4.76) 1.26 (0.39–4.02) 1.64 (0.54–5.00) 1.07 (0.30–3.79) Ref. 0.79 (0.14–4.32) 1.83 (0.58–5.77)
 Model 2 1.04 (0.24–4.48) 1.32 (0.39–4.37) 1.51 (0.48–4.69) 0.93 (0.26–3.35) Ref. 0.67 (0.12–3.70) 1.58 (0.49–5.12)
 Model 3 1.49 (0.32–6.94) 1.68 (0.48–5.83) 1.76 (0.55–5.59) 1.03 (0.28–3.73) Ref. 0.68 (0.12–3.76) 1.41 (0.43–4.62)
 
Age ≥65 years
Men
Number of participants 78 155 127 87 46 41 81
Person-years 855 1,847 1,588 1,169 655 507 1,128
Number of deaths 10 20 13 7 3 6 9
Crude mortality rate 11.7 10.8 8.2 6.0 4.6 11.8 8.0
Hazard ratio (95% CI)              
 Model 1 2.40 (0.65–8.75) 1.99 (0.58–6.73) 1.60 (0.45–5.64) 1.20 (0.31–4.65) Ref. 2.17 (0.54–8.72) 1.61 (0.43–5.95)
 Model 2 4.11 (1.06–15.87) 2.92 (0.82–10.31) 1.96 (0.54–7.03) 1.26 (0.32–4.94) Ref. 1.92 (0.47–7.79) 1.46 (0.38–5.52)
 Model 3 5.20 (1.29–20.90) 3.57 (0.98–12.96) 2.24 (0.61–8.16) 1.38 (0.35–5.41) Ref. 1.92 (0.47–7.76) 1.34 (0.35–5.11)
 
Women
Number of participants 53 166 198 116 95 65 103
Person-years 634 2,336 2,793 1,720 1,444 1,074 1,667
Number of deaths 8 17 15 13 7 5 11
Crude mortality rate 12.6 7.3 5.4 7.6 4.8 4.7 6.6
Hazard ratio (95% CI)              
 Model 1 2.50 (0.90–6.93) 1.38 (0.57–3.35) 1.12 (0.45–2.76) 1.56 (0.62–3.92) Ref. 0.96 (0.30–3.04) 1.45 (0.56–3.76)
 Model 2 2.04 (0.69–5.99) 1.25 (0.51–3.09) 1.05 (0.42–2.63) 1.49 (0.59–2.43) Ref. 0.93 (0.29–2.96) 1.51 (0.58–3.92)
 Model 3 1.83 (0.60–5.53) 1.12 (0.44–2.87) 1.00 (0.39–2.51) 1.47 (0.58–3.72) Ref. 0.95 (0.30–3.05) 1.67 (0.62–4.46)
 
Total
Number of participants 131 321 325 203 141 106 184
Person-years 1,488 4,182 4,381 2,889 2,099 1,581 2,794
Number of deaths 18 37 28 20 10 11 20
Crude mortality rate 12.1 8.8 6.4 6.9 4.8 7.0 7.2
Hazard ratio (95% CI)              
 Model 1 2.33 (1.06–5.08) 1.60 (0.79–3.24) 1.30 (0.63–2.68) 1.37 (0.64–2.95) Ref. 1.36 (0.58–3.22) 1.48 (0.69–3.18)
 Model 2 2.57 (1.13–5.86) 1.70 (0.82–3.51) 1.35 (0.65–2.82) 1.43 (0.66–3.08) Ref. 1.33 (0.56–3.14) 1.49 (0.69–3.21)
 Model 3 2.66 (1.15–6.18) 1.76 (0.83–3.69) 1.38 (0.65–2.90) 1.44 (0.67–3.12) Ref. 1.32 (0.56–3.13) 1.46 (0.67–3.17)

CI, confidence interval; ASCVD, atherosclerotic cardiovascular disease.

Model 1 was adjusted for age.

Model 2 was adjusted for variables in model 1 plus body mass index, total cholesterol, hypertension, diabetes, smoking status, and alcohol drinking status.

Model 3 was adjusted for variables in model 2 plus high-density lipoprotein cholesterol.

The model for total participants (in which the sexes were combined) was also adjusted for sex.

Crude mortality rate is shown as per 1,000 person-years.